COVID-19 Versus Neurological Impairment, Physical Activity, Social Contacts and Education

NCT ID: NCT04934085

Last Updated: 2021-09-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-30

Study Completion Date

2021-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The research will make it possible to assess patients who recovered from COVID-19 for the incidence of neurological problems (impaired balance, gait, coordination, concentration and attention), and changes in the quality of life, physical activity, social contacts and education.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The intended size of group - 100 subjects (50 subjects - study group, 50 subjects - control group). The above population was determined based on sample size calculator, with the following parameters: fraction size of 0.9, Confidence Interval of 95%, maximum error of 9%. The proper study will be preceded with a pilot study involving a smaller group of subjects (in order to standardise the surveys, and minimise the relationship between the results of the survey and side-effect factors). After inclusion and exclusion criteria are considered, the subjects will be allocated into two groups:

* study group (subjects who had tested positive and recovered from COVID-19)
* control group (healthy subjects who did not have COVID-19). The controls will be matched to the study group for gender and age.

The examination will be performed once, at the premises of the University of Rzeszów. The participants' condition will be assessed using the following measures:

* static and dynamic balance and risk of falls (force plate and computerised posturography, clinical tests)
* activity in the cerebral cortex of the frontal lobe during focused performance of a task (Hemoencephalography HEG-System)
* concentration and attention, memory and cognitive functions (Bourdon-Wiersma test and Auditory-Verbal Learning Test)
* gait velocity and efficiency (10-meter walk test and 6-minute walk test)
* physical activity (International Physical Activity Questionnaire IPAQ), as well as education, mood, and social contacts (specially designed questionnaire)
* quality of life (SF-36 questionnaire)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Neurological Disorder Balance; Distorted Gait Disorders, Neurologic Activity, Motor Social Isolation Educational Problems Quality of Life

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

subjects who had tested positive and recovered from COVID-19

No interventions assigned to this group

Control group

healthy subjects who did not have COVID-19, the controls will be matched to the study group for gender and age

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent to participate in the study.
* Experienced infection with SARS-COV-2.
* Age 19 - 26 years
* No injuries to lower limbs in the period of 12 months preceding the date of enrolment into the study
* No orthopaedic disorders affecting the lower limbs (including decreased length of the lower limbs)
* No diagnosed neurological diseases or disorders (including labyrinth dysfunction)
* No diagnosed impairment of concentration and attention

Exclusion Criteria

* Lack of informed consent to participate in the study
* No experience of infection with SARS-COV-2
* Age outside the range of 19 and 27 years
* Confirmed injuries to lower limbs in the period of 12 months preceding the date of enrolment into the study
* Confirmed neurological diseases or disorders, such as impaired balance, concentration and attention.
Minimum Eligible Age

19 Years

Maximum Eligible Age

26 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Rzeszow

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Agnieszka Guzik, PhD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Agnieszka Guzik, PhD

Role: STUDY_CHAIR

University of Rzeszow

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Rzeszów

Rzeszów, Podkarpackie Voivodeship, Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Poland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COVID-19

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.